Clozapine: Dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs

Pharmacology and Toxicology

Volumn 84, Issue 5, 1999, Pages 193-196

  Ahlenius, Sven ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOMETHYL 5,6 DIHYDROXY 3 PHENYLISOCHROMAN; 5 (2,3 DIHYDROBENZOFURAN 7 YL) 2,3,4,5 TETRAHYDRO 3 METHYL 8 NITRO 1H 3 BENZAZEPIN 7 OL; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPEROZIDE; CLOZAPINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; 5 (2,3 DIHYDROBENZOFURAN 7 YL) 3 METHYL 8 NITRO 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 OL; 5-(2,3-DIHYDROBENZOFURAN-7-YL)-3-METHYL-8-NITRO-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPIN-7-OL; BENZAZEPINE DERIVATIVE; BENZOFURAN DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT;

COGNITION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; EXTRAPYRAMIDAL SYSTEM; HUMAN; HYPOTHERMIA; LIGAND BINDING; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SEIZURE THRESHOLD; SIDE EFFECT; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAZEPINES; BENZOFURANS; CLOZAPINE; DOPAMINE ANTAGONISTS; HUMANS; PREFRONTAL CORTEX; RATS; RECEPTORS, DOPAMINE D1;

EID: 0032587634     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1999.tb01482.x     Document Type: Review

References (39)

1. Ahlenius, S.: Strategies for the choice of animal models in the evaluation of atypical antipsychotic drugs. In: Schizophrenia, movement disorders and cognitive disorders relating to aging. Eds.: T. Palomo, T. Archer & B. J. Beninger. Farrand Press, London 1994, pp. 17-31.
2. Ahlenius, S. & J. Engel: Behavioral effects of haloperidol after tyrosine hydroxylase inhibition. Eur. J. Pharmacol. 1971, 15, 187-192.
3. 1 receptor. J. Neurochem. 1986, 47, 1822-1831.
4. Auzou, P., C. Ozsancak, D. Hannequin, N. Moore & P. Augustin: Clozapine for the treatment of psychosis in Parkinson's disease: a review. Acta neurol. scand. 1996, 94, 329-336.
5. 4 receptor antagonist. Trends Pharmacol. Sci. 1997, 18, 186-188.
6. Bruhwyler, J., E. Chleide & M. Mercier: Clozapine: An atypical neuroleptic. Neurosci. Biobehav. Rev. 1990, 14, 357-363.
7. Carlsson, A., T. Persson, B.-E. Roos & J. Wålinder: Potentiation of phenothiazines by α-methyltyrosine in treatment of chronic schizophrenia. J. Neural Transm. 1972, 33, 83-90.
8. Christensson, E. & A. Björk: Amperozide: a new pharmacological approach in the treatment of schizophrenia. Pharmacology & Toxicology 1990, 66 (Supplement I), 5-7.
9. 2 dopamine receptor classification and its functional implications. Synapse 1987, 1, 347-388.
10. Criborn, C.-.O., A. Muren, S. Ahlenius & V. Hillegaart: Effects of lisuride and quinpirole on convulsions induced by hyperbaric oxygen in the mouse. Aviat. Space Environ. Med. 1988, 59, 723-727.
11. Devinsky, O., G. Honigfeld & J. Patin: Clozapine-related seizures. Neurol. 1991, 41, 369-371.
12. Factor, S. A. & J. H. Friedman: The emerging role of clozapine in the treatment of movement disorders. Movement Disorders 1997, 12, 483-496.
13. Farde, L. & G. Sedvall: Chemical brain anatomy of schizophrenia. Lancet 1995, 346, 743-749.
14. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiat. 1988, 45, 71-76.
15. Goldman-Rakic, P. S. & L. D. Selemon: Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schiz. Bull. 1997, 23, 437-458.
16. 1-dopamine receptors. J. Nucl. Med. 1998, 39, 2061-2068.
17. Hippius, H.: The history of clozapine. Psychopharmacol. 1989, 99, S3-S5.
18. Hornykiewicz, O.: The neurochemical basis of the pharmacology of Parkinson's disease. Handb. Exp. Pharmacol. 1989, 88, 185-204.
19. Lewander, T., S. E. Westerbergh & D. Morrison: Clinical profile of remoxipride: A combined analysis of a comparative double-blind multicenter trial program. Acta psychiat. scand. 1990, 82 (Supplementum 358), 92-98.
20. Lidow, M. S., G. V. Williams & P. S. Goldman-Rakic: The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol. Sci. 1998, 19, 136-140.
21. Mansour, A. & S. J. Watson: Dopamine receptor expression in the central nervous system. In: Psychopharmacology: The fourth generation of progress. Eds.: F. E. Bloom & D. J. Kupfer. Raven Press, New York 1995, pp. 207-219.
22. Meltzer, H. Y: Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. 1995, 3, 64-75.
23. 1 values. J. Pharmacol. Exp. Therap. 1989, 251, 238-246.
24. 2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. Amer. J. Psychiat. 1995, 152, 1444-1449.
25. 1 receptors in schizophrenia revealed by PET. Nature 1997, 385, 634-636.
26. Roth, R. H. & J. D. Elsworth: Biochemical pharmacology of midbrain dopamine neurons. In: Psychopharmacology: The fourth generation of progress. Eds.: F. E. Bloom & D. J. Kupfer. Raven Press, New York 1995, pp. 227-243.
27. 2/3 receptors in rat thermoregulation. Brain Res. 1998, 781, 188-193.
28. 1 receptor agonist. Eur. J. Pharmacol. 1996, 307, 27-31.
29. 2 receptors in the regulation of body temperature in the rat. Eur. J. Pharmacol. 1993, 236, 395-400.
30. Salmi, P., T. Karlsson & S. Ahlenius: Antagonism by SCH 23390 of clozapine-induced hypothermia in the rat. Eur. J. Pharmacol. 1994, 253, 67-73.
31. Salmi, P., K. Malmgren, T. H. Svensson & S. Ahlenius: Stimulation of forward locomotion by SCH-23390 and raclopride in d-amphetamine-treated rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 1998, 357, 593-599.
32. 2A receptors in antipsychotic activity. Life Sci. 1995, 56, 2309-2222.
33. Schooler, N. R.: New antipsychotic medications: strategies for evaluation and selected findings. Schiz. Res 1997, 27, 249-259.
34. 4 receptors. Neuropsychopharmacol. 1997, 16, 93-110.
35. Snyder, S. H., D. Greenberg & H. I. Yamamura: Antischizophrenic drugs: Affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects. J. Psychiat. Res 1974, 11, 91-91.
36. Starr, M. S.: The role of dopamine in epilepsy. Synapse 1996, 22, 159-194.
37. 2 receptors as assessed by in vitro and in vivo binding. Eur. J. Pharmacol. 1994, 254, 73-81.
38. Tamminga, C. A. & J. Gerlach: New neuroleptics and experimental antipsychotics in schizophrenia. In: Psychopharmacology: The third generation of progress. Ed.: H. Y. Meltzer. Raven Press, New York 1987, pp. 1129-1140.
39. Wadenberg, M.-.L., S. Ahlenius & T. H. Svensson: Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine. Psychopharmacol. 1993, 110, 273-279.